Loading patent…
AssigneeCalm Water Therapeutics LLC
InventorDavid Maxwell Kleinman
Estimating the term…
Methods for using bioadhesive and stearic interactions specific to copolymers with at least two moieties, to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology. Copolymers have bioadhesive properties driven by electrostatic and hydrophobic interactions and passivation though hydrophilic moieties. These copolymers are useful for reducing rates of viral infectivity in target cells, and in reducing host morbidity. These copolymers are useful for reducing ADC related toxicity including corneal epithelial toxicity. Formulations of these copolymers are safe and well tolerated. Epithelial cells and surfaces including precursor or stem cell corneal epithelial cells are treated with these copolymers to confer utility and benefit.
A method to decrease an ocular adverse event(s) in a patient undergoing antibody-drug conjugate therapy, where said adverse event(s) comprise damage to nonneoplastic cells, the method comprising
A method to decrease an ocular adverse event(s) in a patient undergoing monoclonal antibody therapy, wherein said adverse event(s) comprise damage to the corneal epithelium, said method comprising:
Dependencies are inferred from the claim text.